Syncona Limited

Notice of Final Results

19 May 2023

Syncona Ltd, a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, will announce its preliminary results for the period ended 31 March 2023 on Thursday 15 June 2023.  

An in-person presentation for analysts will take place at 9.00am BST, with a webcast available on the Company's website at https://www.synconaltd.com/ or via this link. Alternatively, please contact Syncona@fticonsulting.com for details of the conference call.

[ENDS]

Enquiries

Syncona Ltd

Annabel Clay / Fergus Witt

Tel: +44 (0) 7714 916615

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses, across development stage and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.